Lose up to 22.5% body weight1
Clinically proven results you can expect associated with weight loss
Improved blood sugar1
Reduced inflammation3
Lower cholesterol1
Lower blood pressure1
Improve heart health3
Clinically monitored
Tailored to you, supported by experts.

Shivani · Lead Clinician
Every patient is clinically assessed, and treatment only begins when it's appropriate. From your first consultation to your long-term health goals, you'll be supported every step of the way.
Programme
More than medication. It's a plan built around you.
1 to 3 months
A clinician assesses your health and prescribes treatment tailored to you. Alongside medication, your dedicated coach helps you build sustainable nutrition habits that support long-term change.
3 to 6 months
Real progress begins to take shape in the form of weight dropping, metabolic health improving, and your clinical team staying close, monitoring your progress and adjusting your treatment as your body responds.
6+ months
At this stage, more people begin to feel the difference, not just on the scales, but in their overall health. Your support continues for as long as you need it.
Begin your journey
Step into better health
Pricing adjusts with your dosage, guided by your clinician. See typical dosage schedule.
People sometimes see this as cheating, but I know it's not. Making a decision to improve your health isn't something you should feel ashamed of.
I can't believe I waited so long to start living my life. Having had that help, I feel better in myself and it was Numan that helped me get there.
After stopping, keeping these healthy habits meant I wasn't putting weight back on. When you see that something's working, you just continue.
It did exactly what I needed it to do. I've been two years away from it now and I feel the healthiest I've felt for years and years.
1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-16.
2. Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-84.
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-32.